Grades 3 to 4 toxic effects of thalidomide in relapsed-refractory patients with MM
| Regimen . | No. patients . | Thrombocytopenia, % . | Neutropenia, % . | Infection, % . | Peripheral neuropathy, % . | Reference . |
|---|---|---|---|---|---|---|
| Thalidomide alone | ||||||
| T | 84 | ND | ND | ND | ND | 9 |
| T | 169 | ND | ND | ND | 9* | 10 |
| TD | 1674 | ND | 11 | ND | 6 | 12 |
| Dexamethasone | ||||||
| TD | 120 | ND | ND | ND | 3 | 17 |
| TD | 44 | ND | ND | ND | ND | 19 |
| Melphalan | ||||||
| TM | 27 | ND | 30† | ND | 40* | 21 |
| MivPT | 24 | 19 | 37 | 8 | 8 | 22 |
| MTD | 21 | 38‡ | 52‡ | ND | 5 | 23 |
| Doxorubicin, TAD | 50 | 2 | 16 | 16 | 2 | 24 |
| Cyclophosphamide | ||||||
| Pulsed CTD | 53 | 2 | 26 | ND | 0 | 27 |
| ThaCyDex | 71 | ND | 10 | 7 | 6* | 28 |
| HyperCTD | 60 | 30 | 86 | 26 | 16 | 29 |
| Regimen . | No. patients . | Thrombocytopenia, % . | Neutropenia, % . | Infection, % . | Peripheral neuropathy, % . | Reference . |
|---|---|---|---|---|---|---|
| Thalidomide alone | ||||||
| T | 84 | ND | ND | ND | ND | 9 |
| T | 169 | ND | ND | ND | 9* | 10 |
| TD | 1674 | ND | 11 | ND | 6 | 12 |
| Dexamethasone | ||||||
| TD | 120 | ND | ND | ND | 3 | 17 |
| TD | 44 | ND | ND | ND | ND | 19 |
| Melphalan | ||||||
| TM | 27 | ND | 30† | ND | 40* | 21 |
| MivPT | 24 | 19 | 37 | 8 | 8 | 22 |
| MTD | 21 | 38‡ | 52‡ | ND | 5 | 23 |
| Doxorubicin, TAD | 50 | 2 | 16 | 16 | 2 | 24 |
| Cyclophosphamide | ||||||
| Pulsed CTD | 53 | 2 | 26 | ND | 0 | 27 |
| ThaCyDex | 71 | ND | 10 | 7 | 6* | 28 |
| HyperCTD | 60 | 30 | 86 | 26 | 16 | 29 |